COVID-19-Associated Disease Course Is Shortened in Moderate-to-Severe Atopic Dermatitis Patients Receiving Dupilumab Treatment: A Retrospective Cross-Sectional Study.

J Clin Med · 2023 · PMC10219280 · PMID 37240520

Europe PMC DOI

hedged sentences

—

closest p

—

boldest claim

The sentences

borderline significantno p-value reported

In this study, we could not draw the conclusion that dupilumab treatment remarkably improves COVID-19 symptom severity score because the p -value (0.059) was borderline significant, probably, also due to the small sample size.

also in 3,262 other papers

close to the limit of significanceno p-value reported

In the present study, we found that in comparison with the healthy control group and topical treatment group, moderate-to-severe AD patients treated with dupilumab had the shortest COVID-19-associated disease course, although p -value (0.046) from the dupilumab treatment group compared with the topical treatment group was close to the limit of significance, which may be explained by the small sample size.

also in 19 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.